{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:28:59Z","timestamp":1790908139939,"version":"4.1.0"},"reference-count":59,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2003,5,30]],"date-time":"2003-05-30T00:00:00Z","timestamp":1054252800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2003,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>In vitro and clinical data suggest a therapeutic role for \u03b12 interferon (IFN) in the treatment of the chronic myeloproliferative disorders. Accordingly, a multiinstitutional, Phase II trial of IFN in patients with agnogenic myeloid metaplasia (AMM), essential thrombocythemia (ET), and polycythemia rubra vera (PRV) in the <jats:italic>spent<\/jats:italic> phase was initiated. The objectives of this study were 1) to investigate the response rates that may be achieved with IFN in the treatment of patients with these disorders, 2) to estimate the durability of the responses, and 3) to assess the toxicities of IFN in these populations.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Enrollment was limited to patients with AMM, ET, or PRV who already had developed 1) anemia or transfusion dependency, 2) thrombocytosis uncontrolled by standard therapy, 3) hemostatic complications, or 4) symptomatic splenomegaly. Initially, patients were started on IFN at a dose of 5 MU\/m<jats:sup>2<\/jats:sup> per day as a subcutaneous injection. After the first 16 patients had been treated, the starting dose of IFN was reduced to 2 MU\/m<jats:sup>2<\/jats:sup> per day because of unexpected toxicities.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>IFN demonstrated different levels of efficacy and toxicity in each of the three diseases studied. The overall response rates achieved among the evaluable patients in each category were as follows: ET, 88.2% (<jats:italic>n<\/jats:italic> = 17 patients; 1 complete response and 14 partial responses); PRV, 41.7% (<jats:italic>n<\/jats:italic> = 12 patients; 1 complete response and 4 partial responses); and AMM, 3.2% (<jats:italic>n<\/jats:italic> = 31 patients; 0 complete responses and 1 partial response). Thrombocytosis and leukocytosis were controlled in nearly all patients, with reversal of splenomegaly and resorption of myelofibrosis achieved in fewer patients. The toxicities attributed to IFN differed notably among the three disease groups: patients who had AMM suffered systemic and neurologic toxicities more frequently than patients who had PRV or ET; whereas patients who had ET experienced a greater than expected incidence of hepatic abnormalities, most typically transient elevations of serum amino acid transaminase levels.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>The current study demonstrated the safety and efficacy of IFN in patients with ET, PRV, and AMM. Objective responses and\/or disease stabilization were obtained in patients with all three disease entities, including the reversal of splenomegaly and resorption of myelofibrosis in some patients. Cancer 2003;98:100\u20139. \u00a9 2003 American Cancer Society.<\/jats:p><jats:p>DOI 10.1002\/cncr.11486<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.11486","type":"journal-article","created":{"date-parts":[[2003,6,23]],"date-time":"2003-06-23T12:15:02Z","timestamp":1056370502000},"page":"100-109","source":"Crossref","is-referenced-by-count":42,"title":["Phase II study of \u03b12 interferon in the treatment of the chronic myeloproliferative disorders (E5487)"],"prefix":"10.1002","volume":"98","author":[{"given":"Arthur I.","family":"Radin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haesook T.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara W.","family":"Grant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Kirkwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard G.","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice P.","family":"Dutcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter H.","family":"Wiernik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin M.","family":"Oken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2003,5,30]]},"reference":[{"key":"e_1_2_5_2_2","first-page":"1048","article-title":"Inhibitory effects of interferons on mouse megakaryocytic progenitor cells in culture","volume":"8","author":"Dukes PP","year":"1980","journal-title":"Exp Hematol."},{"key":"e_1_2_5_3_2","first-page":"587","article-title":"Effect of interferon on pleuripotent hemopoietic progenitors (CFU\u2010GEMM) derived from human bone marrow","volume":"10","author":"Neumann HA","year":"1982","journal-title":"Exp Hematol."},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V70.4.1014.1014"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/140.4.560"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.282.6273.1345"},{"key":"e_1_2_5_7_2","first-page":"4458","article-title":"Phase I study of pharmacological and immunological effects of human lymphoblastoid interferon given to patients with cancer","volume":"43","author":"Laszlo J","year":"1983","journal-title":"Cancer Res."},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1984.101"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1984.2.4.336"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198401053100104"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(84)92377-8"},{"key":"e_1_2_5_12_2","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1182\/blood.V65.3.644.644","article-title":"Treatment of hairy cell leukemia with recombinant alpha2 interferon","volume":"65","author":"Ratain MJ","year":"1985","journal-title":"Blood."},{"key":"e_1_2_5_13_2","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1182\/blood.V67.3.817.817","article-title":"Treatment of hairy cell leukemia with recombinant alpha interferon: I. Quantitative study of bone marrow changes during the first month of treatment","volume":"67","author":"Flandrin G","year":"1986","journal-title":"Blood."},{"issue":"8","key":"e_1_2_5_14_2","first-page":"1678","article-title":"Interferon alpha in the treatment of hairy cell leukemia","volume":"57","author":"Castaigne S","year":"1986","journal-title":"Cancer."},{"issue":"1","key":"e_1_2_5_15_2","first-page":"559","article-title":"Clinical investigation of human leukocyte interferon in chronic myelogenous leukemia","volume":"60","author":"Talpaz M","year":"1982","journal-title":"Blood."},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(84)90282-1"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-4827(79)90450-6"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.159.6.1741"},{"key":"e_1_2_5_19_2","first-page":"2358","article-title":"Interferon\u2010induced cell cycle changes in human hematopoietic cell lines and fresh leukemic cells","volume":"44","author":"Roos G","year":"1984","journal-title":"Cancer Res."},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-4827(84)90780-8"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.85.1.9"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI111480"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(84)90422-4"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI112945"},{"key":"e_1_2_5_25_2","first-page":"516","article-title":"Interferon\u2010antitumor actions","volume":"16","author":"Fleischmann WR","year":"1984","journal-title":"Transplant Proc."},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198604243141701"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-99-6-789"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2400885"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(88)90664-2"},{"key":"e_1_2_5_30_2","first-page":"83","article-title":"Interferon therapy for agnogenic myeloid metaplasia complicated by immune hemolytic anemia","volume":"5","author":"Radin AI","year":"1991","journal-title":"Hematol Pathol."},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198212000-00014"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.2307\/2530297"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21979"},{"issue":"4","key":"e_1_2_5_34_2","first-page":"236A","article-title":"Toxicity of interferon\u2010alpha2 in the chronic myeloproliferative disorders: preliminary results of a collaborative Phase II trial","volume":"74","author":"Radin AI","year":"1989","journal-title":"Blood."},{"issue":"3","key":"e_1_2_5_35_2","first-page":"6","article-title":"Interferon in the treatment of myeloproliferative diseases","volume":"27","author":"Silver RT","year":"1990","journal-title":"Semin Hematol."},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-114-7-532"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1988.tb00212.x"},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198805193182002"},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0268-960X(97)90001-1"},{"key":"e_1_2_5_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(87)92656-0"},{"key":"e_1_2_5_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1987.tb00762.x"},{"key":"e_1_2_5_42_2","first-page":"545a","article-title":"Regression of myeloid metaplasia during interferon alpha\u20102b treatment of myeloproliferative disease is accompanied by reduction in circulating concentrations of colony stimulating factor\u20101","volume":"37","author":"Gilbert HS","year":"1989","journal-title":"Clin Res."},{"key":"e_1_2_5_43_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002770050554"},{"key":"e_1_2_5_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)92142-9"},{"key":"e_1_2_5_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(88)90005-0"},{"key":"e_1_2_5_46_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1989.tb04251.x"},{"issue":"52","key":"e_1_2_5_47_2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1600-0609.1990.tb00899.x","article-title":"Therapy of essential thrombocythemia with alpha\u2010interferon: results and prospects","volume":"45","author":"Lazzarino M","year":"1990","journal-title":"Eur J Hematol."},{"key":"e_1_2_5_48_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1991.tb08118.x"},{"key":"e_1_2_5_49_2","first-page":"75","article-title":"Alpha\u2010interferon in polycythemia vera and essential thrombocythemia","volume":"76","author":"Turri D","year":"1991","journal-title":"Haematologica."},{"key":"e_1_2_5_50_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V77.10.2103.2103"},{"key":"e_1_2_5_51_2","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1182\/blood.V76.4.664.664","article-title":"A new treatment for polycythemia vera: recombinant interferon\u2010alpha","volume":"76","author":"Silver RT","year":"1990","journal-title":"Blood."},{"key":"e_1_2_5_52_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-119-11-199312010-00006"},{"key":"e_1_2_5_53_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830440303"},{"key":"e_1_2_5_54_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01697629"},{"key":"e_1_2_5_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0344-0338(11)80116-0"},{"key":"e_1_2_5_56_2","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/(SICI)1097-0142(19980915)83:6<1205::AID-CNCR21>3.0.CO;2-8","article-title":"Long term treatment of myeloproliferative disease with interferon\u2010alpha\u20102b: feasibility and efficacy","volume":"1583","author":"Gilbert HS","year":"1998","journal-title":"Cancer."},{"key":"e_1_2_5_57_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199509059658"},{"key":"e_1_2_5_58_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10663"},{"key":"e_1_2_5_59_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.6.1708"},{"key":"e_1_2_5_60_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-002-0533-4"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.11486","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.11486","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T14:25:59Z","timestamp":1760279159000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.11486"}},"subtitle":["<i>A trial of the Eastern Cooperative Oncology Group<\/i>"],"short-title":[],"issued":{"date-parts":[[2003,5,30]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2003,7]]}},"alternative-id":["10.1002\/cncr.11486"],"URL":"https:\/\/doi.org\/10.1002\/cncr.11486","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,5,30]]}}}